SOURCE: Chembio Diagnostics, Inc.

March 29, 2007 09:14 ET

Chembio Reports Fourth Quarter and Full-Year 2006 Results

MEDFORD, NY -- (MARKET WIRE) -- March 29, 2007 -- Chembio Diagnostics, Inc. (OTCBB: CEMI) reported fourth quarter and full-year financial results for 2006.

2006 revenues were $6.5 million, a 65% increase compared to 2005 revenues of $3.9 million. For 2006, the net loss attributable to common stockholders was $8.2 million or $0.80 per share compared to a net loss attributable to common stockholders of $6.8 million or $0.88 per share for 2005. The net loss attributable to common stockholders for 2006 and 2005 includes $3.0 million and $3.52 million, respectively, for non-cash dividends as well as the beneficial conversion feature related to the Company's convertible preferred stock.

Revenues for the fourth quarter of 2006 were $2.6 million, a 93% increase compared to fourth quarter 2005 revenues of $1.4 million. The fourth quarter 2006 net loss attributable to common stockholders was $2.6 million or $.23 per share compared to a net loss attributable to common stockholders of $1.14 million or $.14 per share for the fourth quarter of 2005. The net loss attributable to common stockholders for the fourth quarters of 2006 and 2005 include $1.5 million and $.2 million, respectively, for non-cash dividends as well as the beneficial conversion feature related to the Company's convertible preferred stock.

The fourth quarter and full-year revenue growth was attributable to increased sales of the Company's rapid HIV and Chagas Disease tests.

Financial Outlook

The Company believes that sales of its HIV products will continue to increase in 2007 as a result of both sales to the United States market through our U.S. marketing agreement with Inverness Medical Innovations, Inc. (Inverness) and the international marketing strategies that were implemented in 2006. The Company also expects to begin to generate additional revenues in 2007 from its veterinary line of STAT-PAK™ rapid tests and from its recently patented Dual Path Platform (DPP™) technology. In view of these developments together with the financings that the Company has completed, the "going concern" qualification contained in the previous audit report from the Company's independent auditors has been removed in the current annual report.

Company Highlights In 2006 Chembio:

--  Received FDA approval of SURE CHECK™ HIV and HIV 1/2 STAT-PAK™
    in May 2006.
--  Received Clinical Laboratory Improvement Act (CLIA) waiver of HIV 1/2
    STAT-PAK in November 2006, allowing this test to be sold into approximately
    189,000 laboratory entities across the United States, including doctors'
    offices and clinics.  CLIA waiver for SURE CHECK (now under Inverness
    brand) is still pending.
--  Concluded in September 2006 three agreements with Inverness Medical
    Innovations, Inc., a leader in point of care diagnostics for both consumer
    and professional markets. Inverness launched this quarter Chembio's two FDA
    approved rapid HIV tests. Inverness also granted Chembio a license to its
    lateral flow intellectual property and invested $2 million in the Chembio
    Series C Convertible Preferred Stock financing.
--  Completed private placement transactions in the total amount of
    approximately $10 million, including $8.25 million of Series C 7%
    Convertible Preferred Stock together with warrants to purchase common
--  Settled costly litigation with StatSure Diagnostic Systems (SDS) which
    settlement combines each company's HIV barrel intellectual property,
    including an exclusive manufacturing license from StatSure to Chembio of
    its barrel patent for all HIV applications.
--  Was the only U.S.-based manufacturer of rapid HIV tests selected by
    the Clinton Foundation HIV/AIDS Initiative (CHAI) and was also selected in
    four of the eight parallel testing algorithms adopted by the Nigerian
    Ministry of Health, the latter resulting in significant revenues in 2006.
    The possible selection of Chembio's tests in additional African countries
    is pending.
--  Received an order for 990,000 of our Sure Check product from our
    distributor in Mexico.  Approximately one-half of this order was shipped
    during the fourth quarter of 2006 and the balance was shipped during the
    first quarter of 2007.
--  Shipped its first significant order for the Chagas STAT-PAK™ rapid
    test, in the amount of $1.2 million, in 2006.
"2006 was a landmark year for Chembio Diagnostics, and 2007 has begun splendidly with the issuance of our Dual Path Immunoassay Device patent as recently announced," said Lawrence Siebert, President and CEO. "We believe the US rapid HIV test market will grow as a result of the September 2006 recommendations issued by the United States Centers for Disease Control for routine HIV testing as well as the March 2006 decision by the US Food & Drug Administration to allow qualifying HIV tests to be submitted for approval for the over-the-counter market. These developments should help drive the expansion of the U.S. market for our products and technologies, and we believe our US marketing partner is well positioned to maximize this opportunity. We also have completed the facility inspection by the United States Department of Agriculture, which should result in our first veterinary product approval very soon. With increasing US-market revenues from our HIV tests and initial sales from our veterinary products, we believe that our operating results should improve, due both to increased unit volumes and higher average unit selling prices. Regardless we are focused on driving our manufacturing costs down with better plant utilization, more automation and other strategies."

Mr. Siebert further stated, "We also would like to thank both our shareholders for the confidence that they have expressed in Chembio during this past year and our employees for their dedication and hard work."

                        Chembio Diagnostics, Inc.
                     Summary of Results of Operations

                                                   Fourth        Fourth
                        2006          2005      Quarter 2006  Quarter 2005
                    ============  ============  ============  ============
Total Revenues      $  6,502,480  $  3,940,730  $  2,609,387  $  1,358,443

Gross Profit           2,016,568     1,332,146       829,224       520,606

Operating Loss        (4,580,193)   (3,297,987)     (964,453)     (946,766)

Net Loss              (4,995,020)   (3,252,000)   (1,029,944)     (923,366)

Preferred Dividends    3,210,046     3,517,022     1,566,283       217,826

Net Loss
 Attributable to
 Stockholders       $ (8,205,066) $ (6,769,022) $ (2,596,227) $ (1,141,192)

Loss per share      $      (0.80) $      (0.88) $      (0.23) $      (0.14)


Chembio Diagnostics, Inc. is a developer and manufacturer of rapid diagnostic tests for infectious diseases. The Company has received marketing approval from the FDA for two of its rapid HIV tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP™), for its next generation HIV and other rapid tests. References to Chembio may also include its wholly owned operating subsidiary, Chembio Diagnostic Systems, Inc. For additional information please visit


Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact Information

    Chembio Diagnostics, Inc.
    Matty Arce
    631-924-1135 ext 123.